Company intelligence / Profile preview

Delta Crystallon

Dublin, Dublin, Irelandpmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

The company has completed a Phase 2 clinical trial (NCT02442570) evaluating the safety and clinical efficacy of DC-TAB in multiple sclerosis. They have also completed a Phase 1 trial (NL-OMON34913) to evaluate safety, tolerability, pharmacokinetics, and T-cell tolerizing effect of DC-TAB in healthy volunteers.

Therapeutic areas: Neurology
Modalities: Recombinant protein
Industry: Biotech

Drug pipeline

1 asset

HspB5

Phase 2

Indications: Multiple sclerosis, Pneumococcal meningitis, Sensorineural hearing loss

Partnerships

Serenity Bioworks

Beyond the preview

Go deeper on Delta Crystallon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Delta Crystallon.

Explore the full profile